- AsymBio has established integrated technology platforms spanning the full biopharmaceutical development lifecycle, from early development to commercial manufacturing.
- Its capabilities include cell line development, upstream and downstream processing, conjugation technologies, drug product development, payload-linker CMC, and analytical services, supporting more than 70 IND and 13 NDA projects.
AsymBio, a subsidiary of Asymchem Group, announced it has established integrated technology platforms covering the full biopharmaceutical development lifecycle. The company said its end-to-end CDMO and contract manufacturing services provide streamlined workflows for client programs from early development through commercial production.
The technology-driven biopharmaceutical CDMO has built multiple core platforms. These include the AmigoCHO™ cell line development platform, upstream and downstream process development platforms, and a modular Conjugation Toolbox supporting ADCs and other bioconjugate modalities. The upstream process platform supports preclinical material preparation, IND/BLA-enabling development, and scale-up, with timelines shortened to as little as nine weeks.
AsymBio has also established an IMPACT drug product development platform supporting high-concentration, lyophilized, liquid, and frozen-liquid presentations. Its payload-linker CMC development platform offers multiple payload and linker options and supports more than 70 IND and 13 NDA projects. The company’s comprehensive analytical platform provides analytical method development and product characterization across the product lifecycle.
The Conjugation Toolbox was shortlisted in the “Best ADC Platform Technology” category at the 2025 World ADC Awards. The platform supports multiple conjugation approaches, including cysteine- and lysine-based methods, enzymatic techniques, glyco-remodeling, and interchain cysteine re-bridging.
The company stated it will continue investing in research and development and advanced technology platforms. It said integrating scientific approaches with large-scale manufacturing experience supports improved manufacturing efficiency, product quality, and the commercialization of innovative therapies for global clients.
